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BACKGROUND
• Traumatic brain injury (TBI), a common condition 
seen in both adults and children, can lead to 
cognitive, social and physical complications. 
• Attention Deficit/Hyperactivity Disorder (ADHD) 
induced by TBI (secondary ADHD or ADHD/TBI) in 
children is one consequence that has limited 
discussion in the literature.
OBJECTIVE
This poster reviews the psychopharmacologic 
treatment options available, their effectiveness, and 
what is currently under study.
METHODS
• A literature search was conducted using the following 
databases: Medline, Cochrane/EBM and PubMed 
from 1988-2011.
• Stimulants TBI, TBI, ADHD TBI, Bromocriptine, 
Guanfacine, Donepazil and Atomoxetine were the 
key search terms used.
• Limits include clinical trial publication, human 
subjects, English language, adults and children age 
0-18 years.
• Information was extracted on study characteristics, 
interventions and outcome.
• Data extracted included subjective and objective 
tests use to measure behavioral and cognitive 
outcomes. (see details in Tables)
RESULTS
• Eleven clinical trials evaluating the efficacy and 
safety of Methylphenidate (MPH) in pediatric and 
adult patients with TBI match the search criteria. 
(see details in Table 1)
• Methylphenidate administration resulted in a 
statistically significant increase in pulse of 12.3 
beats/min (95% confidence interval (CI) 9.25–15.36), 
diastolic blood pressure of 4.1 mmHg (95% CI 2.11–
6.10), and mean arterial pressure of 3.75 mmHg 
(95% CI 1.79–5.72). These changes did not, 
however, appear to be symptomatic, as no 
participants were withdrawn due to adverse 
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events, and there was no significant self-report of 
increased heart rate with methylphenidate.
(Catherine Willmott et. al 2009)
• Methylphenidate was safely used in brain injured 
patients, even those at high risk for seizures, as it 
was associated with a trend toward reduction 
(rather than increase) in seizure frequency in this 
population. (Wroblewski et. al, 1992)
• (See results of published clinical studies on non-
stimulant medications in secondary ADHD in 
Table 2.)
• Many drugs showed encouraging pre-clinical 
results with neuroprotective, 
neurorestorative, neurogenetic 
and synaptogenetic properties but all phase II and 
III clinical trials have failed so far. They include 
Progesterone, Dexabinol, Dexamethasone 
Magnesium, Cyclosporin A, Erythropoietin (and its 
carbamylated form), Statins, and Bone marrow 
stromal cells. (Robert Vink et. al ’04), (Ye-Xione et. al ’09)
CONCLUSION
• There are a limited number of randomized double 
blind placebo controlled multicenter trials studying 
the effects of methylphenidate in ADHD/TBI.
• No randomized controlled studies in ADHD/TBI 
using stimulants other than MPH were found.
• Statistical analyses of the limited data 
demonstrate the efficacy of short term treatment 
with MPH in the pediatric population.
• There is very scant literature available on the use 
of non stimulant treatment options in Secondary 
ADHD.
RECOMMENDATIONS
• More studies are required to see the effects of 
amphetamine group of stimulants and non-
stimulant treatment options for secondary ADHD. 
• Based on our review, additional multicenter, 
randomized, double blind, placebo controlled 
studies with larger sample sizes, longer length of 
treatment and wider dose ranges would be 
helpful in guiding clinical practice. 














Gualtieri et al. 
(1998)
R, DB, PC, 
crossover
15 <8 5 mo-12 y 12 0.15-0.30 Attention, memory Some symptomatic improvement in memory




38 <8 >=6 mo 42 4 wks 
titration 30 
mg/day at 
wk 5 & 6
Anger, memory, attention 
psychological and social 
adjustment, adverse effects
Effective in anger, memory improvement
Speech et al. 
(1993)
R, DB, PC 12 NR 14 mo-9 y 7 0.3 Attention, learning, 
cognitive processing speed, 
social behavior
No significant difference in methylphenidate 
vs placebo




10 NR 2 mo – 9y 4 0.25 – 0.35 Attention, memory, 
behavior, processing speed, 
psychomotor speed
No significant difference in any outcomes 
with methylphenidate vs placebo
Mahalick et al. 
(1998)
R, DB, PC, 
crossover
14 3-15 1 mo- 5 y 14 0.3 Attention disorders Significant improvement in all tasks of 
attention and concentration with 
methylphenidate vs placebo






10 3-13 4 days – 2 mo Attention, functional 
outcome 
Significant improvement in attention with 
methylphenidate vs natural recovery
Whyte et 
al.(1997)
R, DB, PC, 
crossover
19 3-14 1 mo – 8 y N/A 0.25 Attention Significant improvement in mental processing 
speed
Whyte et al. 
(2004)
R, DB, PC, 
crossover
34 <12 >= 3 mo Attention Improvement in the speed of processing 
information, some aspects of on-tasks 
behavior improved with methylphenidate 
Plenger et al. 
(1996)
R, DB, PC, 
crossover
23 4-132 NR Attention, memory, 
vigilance
Attention and motor function improved with 
methylphenidate at 30 day evaluation
Alban et al. 
(2004)
R, DB, PC, 
crossover
35 <12 4 mo-34 y Adverse effects, vital signs Poor appetite, mean rise in arterial pressure 
2.5 mm Hg, pulse increased by 7 beats/min
Hornyak et al. 
(1996)











Attention Improvement in attention, impulsivity, level 
of activity, agitation, responsivity and arousal
DB = double-blind; GCS = Glasgow Coma Scale; NR = not reported; PC = placebo-controlled; R = randomized; TBI = traumatic brain injury
1 The following scores indicate the severity of TBI; severe 1-8; moderate 9-12; and mild 13-15
2 Complicated, mild to moderately severe TBI
Table 1: Published Clinical Studies for Methylphenidate in TBI
Reference Medication Design Pts (N) Duration of 
Treatment 
Dose Used Outcome 
Measures
Results
Zhang et al. 
(2004)
Donepazil R, DB, PC, 
Crossover







neuropsychologic testing scores 
in short- term memory and 
sustained attention.
Whyte jet et 
al. (2008)
Bromocriptine DB, PC, 
Crossover
12 6 wks 5 mg BID Attention and 
work 
productivity
Bromocriptine in a dose of 5 mg 
BID does not seen to enhance 
attentional skills, and it may be 
associated with an excess of 
adverse events. It is not clear 
whether intermediate dosing or 










13 37 days 2 mg daily Working 
memory (ability 
to hold info in 
mind) No info 
on attentional 
component
It is associated with increased 
working memory performance. 
Wendy M 
Reid et al. 
(2008)
Atomoxetine - - - - - Improves cognition Following 
experimental TBI in animals. No 
study on human subjects.
Table 2: Published Clinical Studies on Non-Stimulant 
Medication in Secondary ADHD
